| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFα inhibitors.
|
Ann Rheum Dis
|
2011
|
1.10
|
|
2
|
Radiographic progression is associated with resolution of systemic inflammation in patients with axial spondylarthritis treated with tumor necrosis factor α inhibitors: a study of radiographic progression, inflammation on magnetic resonance imaging, and circulating biomarkers of inflammation, angiogenesis, and cartilage and bone turnover.
|
Arthritis Rheum
|
2011
|
1.04
|
|
3
|
Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors.
|
Ann Rheum Dis
|
2009
|
0.95
|
|
4
|
Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFα inhibitors.
|
Clin Rheumatol
|
2010
|
0.92
|
|
5
|
Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment.
|
Dan Med J
|
2012
|
0.80
|
|
6
|
No overall damage progression despite persistent inflammation in adalimumab-treated psoriatic arthritis patients: results from an investigator-initiated 48-week comparative magnetic resonance imaging, computed tomography and radiography trial.
|
Rheumatology (Oxford)
|
2013
|
0.79
|
|
7
|
[Rheumatology in 2008. The Danish Society of Rheumatology].
|
Ugeskr Laeger
|
2008
|
0.75
|
|
8
|
[Post-partum transient osteoporosis of the hip causing pain].
|
Ugeskr Laeger
|
2014
|
0.75
|
|
9
|
[Danish recommendations on treatment of ankylosing spondylitis and spondyloarthritis based on multinational project initiative].
|
Ugeskr Laeger
|
2008
|
0.75
|
|
10
|
[Simultaneous presence of Takayasu's arteritis and factor V Leiden thrombophilia].
|
Ugeskr Laeger
|
2005
|
0.75
|
|
11
|
Evidence-based recommendations for treatment with methotrexate in rheumatic disorders.
|
Dan Med Bull
|
2010
|
0.75
|